G-CSFバイオ後発品の臨床的有用性の評価

文献

J-GLOBAL ID：201702274437315488 整理番号：17A0155799

Evaluation of the Clinical Benefit of a G-CSF Biosimilar

出版者サイト {{ this.onShowPLink() }} 複写サービスで全文入手 {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=17A0155799&COPY=1") }}
高度な検索・分析はJDreamⅢで {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0155799&from=J-GLOBAL&jstjournalNo=F1425A") }}

著者 (9件)： , , , , , , , ,
資料名：
巻： 7 号： 1 ページ： 3-15 発行年： 2017年01月31日
JST資料番号： F1425A ISSN： 2185-7113 資料種別：逐次刊行物 (A)
記事区分：原著論文発行国：日本 (JPN) 言語：英語 (EN)

バイオ医薬品は,一般的に有用性は高いが,高薬価のため医療費高...

,...
,...

続きはJDreamIII（有料）にて {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0155799&from=J-GLOBAL&jstjournalNo=F1425A") }}

血液・体液作用薬の臨床への応用 , 血液疾患の薬物療法

引用文献 (12件)：

1) Medical Economic Division, Health Insurance Bureau, Ministry of Health Labour and Welfare. On the Drug Pricing Standards. Office Memorandum, February 10, 2016. http://www.ajha.or.jp/admininfo/pdf/2016/160215_1.pdf
2) Report article on the symposium titled “Toward development of biosimilars and promotion of their use” in 9^th Academic Meeting of Japan Society of Generic Medicines, Hamamatsu, June 13, 2015. Pharmacist Magazine, June 17, 2015. AIDEM Expert: https://www.pharmacist-magazine.com/news/article/1161.html
3) Ministry of Health Labour Welfare. Promotion of use of generic medicines. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/kouhatu-iyaku/
4) Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma. 2009; 50: 374-379.
5) Kiyama S, Kimura Y, Sakoda K, Nakamura M, Hamasaki S, Miura H et al. Investigation of the effectiveness of an original filgrastim drug and a biosimilar. J Jpn Soc Hosp Pharm. 2015; 51: 867-870.

, , ,

前のページに戻る